Related Experiment Video
Updated: Dec 8, 2025

High-throughput Measurement of Plasma Membrane Resealing Efficiency in Mammalian Cells
Published on: January 7, 2019
A Choline-Recognizing Monomeric Lysin, ClyJ-3m, Shows Elevated Activity against Streptococcus pneumoniae
Dehua Luo1, Li Huang2, Vijay Singh Gondil3
1State Key Laboratory of Agricultural Microbiology, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Engineered bacteriophage lysin ClyJ-3m, a monomer, shows enhanced bactericidal activity against Streptococcus pneumoniae. This novel lysin offers improved protection in infection models and better pharmacokinetic properties than its predecessor.
Area of Science:
- Microbiology
- Biochemistry
- Pharmacology
Background:
- * Streptococcus pneumoniae* is a major cause of bacterial pneumonia.
- * Bacteriophage lysins with choline-binding modules (CBMs) are effective antimicrobials.
- * ClyJ is a pneumococcus-specific lysin, with ClyJ-3 variant showing improved activity.
Purpose of the Study:
- * To engineer a novel variant of ClyJ-3, named ClyJ-3m, by deleting its C-terminal tail.
- * To evaluate the bactericidal activity and pharmacokinetic properties of ClyJ-3m.
- * To assess the therapeutic efficacy of ClyJ-3m in a *S. pneumoniae* bacteremia model.
Main Methods:
- * Construction and biochemical characterization of ClyJ-3m, a monomeric lysin.
- * In vitro assessment of bactericidal activity against various *S. pneumoniae* serotypes.
- * In vivo evaluation in a murine bacteremia model and pharmacokinetic analysis.
Main Results:
- * ClyJ-3m functions as a monomer upon choline binding, unlike the dimeric ClyJ-3.
- * ClyJ-3m demonstrated superior bactericidal activity against multiple pneumococcal strains.
- * ClyJ-3m provided significantly higher protection (70%) in a murine bacteremia model compared to ClyJ-3 (20%).
- * Pharmacokinetic studies showed ClyJ-3m has reduced clearance and a greater area under the curve than ClyJ-3.
Conclusions:
- * The engineered monomeric lysin ClyJ-3m exhibits enhanced bactericidal efficacy and improved pharmacokinetic profiles.
- * ClyJ-3m represents a promising therapeutic candidate for treating *Streptococcus pneumoniae* infections.
- * This study offers a novel strategy for designing and engineering bacteriophage lysins for targeted antimicrobial therapy.
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Direct-Acting Cholinergic Agonists: Therapeutic Uses
Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Direct-Acting Cholinergic Agonists: Pharmacokinetics

